VectorY Therapeutics hires Jessica Atkinson as new Chief Business Officer
In a significant move, VectorY Therapeutics, a company dedicated to providing treatments for neurodegenerative diseases, has announced the appointment of Jessica Atkinson as its new Chief Business Officer. This strategic hire is expected to play a crucial role in shaping the long-term commercial strategy and forging key partnerships for the company.
VectorY's unique approach to treating neurodegenerative diseases involves the development of vectorized antibody therapies. By combining precise therapeutic antibodies with one-time AAV-based delivery to the Central Nervous System (CNS), the company aims to address the underlying mechanisms of diseases such as ALS and Huntington's disease. This innovative strategy seeks to overcome limitations of traditional antibody therapies, including poor brain penetration and short half-life, by using viral vectors to deliver antibodies that can modify disease progression.
Jessica Atkinson brings over two decades of experience in business development and commercialization to the role, having held leadership positions at ImmuneID, Glympse Bio, Foundation Medicine, and Merck & Co. Most recently, she served as a fractional CBO or strategic advisor to multiple early-stage biotech companies through her consulting firm, TwoStep Advisors.
In her new position, Atkinson will work closely with the CEO and leadership team to shape VectorY’s long-term commercial strategy and drive strategic partnerships. Her expertise is expected to accelerate VectorY's program development and market positioning, enabling the company to effectively transition its innovative therapies from research to clinical and commercial stages.
Jim Scibetta, CEO of VectorY Therapeutics, expressed his delight at Atkinson's appointment, stating, "Jessica's extensive experience in the biopharma industry will be instrumental in helping us advance our mission to provide a longer, better life for people with neurodegenerative diseases."
For media inquiries, contact Vigo Consulting at [email protected] or Tel: +44 207 390 0237 / +44 20 7390 0231. For more information about VectorY Therapeutics, visit their website at www.vectorytx.com.
With this strategic appointment, VectorY Therapeutics continues to make significant strides in its mission to rapidly develop disease-modifying therapies for neurodegenerative diseases. The company's integrated approach aims to translate promising science into impactful treatments for patients with neurodegenerative conditions, leveraging expertise in both innovation and business execution.
- The news of Jessica Atkinson's appointment as VectorY Therapeutics' new Chief Business Officer has been making rounds in health-and-wellness and finance media, highlighting her role in shaping the long-term commercial strategy and forging key partnerships for the medical-conditions focus company.
- In a move that strengthens VectorY Therapeutics' business approach, Atkinson, with her extensive experience in the biopharma industry, will collaborate with the CEO and leadership team to advance the company's science in treating neurodegenerative diseases like ALS and Huntington's, potentially impacting health-and-wellness by transitioning innovative therapies into clinical and commercial stages.
- As the company delves deeper into developing vectorized antibody therapies and works on addressing the challenges of traditional therapies, their strategic hire, Jessica Atkinson, is anticipated to accelerate the progress in cloud computing and data management, setting the stage for smooth business operations and effective growth in the finance sector.
